Enveda, founded in 2019 in Boulder, Colorado, uses its Prism platform and mass spectrometry to find drug candidates in compounds made by plants and microbes. It raised a $311 million Series E led by Catalio Capital Management in September 2026, valuing it at about $2 billion.
At a glance
| Price from | Custom |
| Best for | Investors and partners tracking clinical-stage AI drugs |
From Enveda's own website.
What stands out
- Three candidates in clinical trials
- Distinct natural-chemistry approach
Worth knowing
- Clinical data still early
- Focus on natural compounds narrows scope
How it ranks
Enveda is ranked 4th of 10 in Best AI Drug Discovery Startups (Lister Score 93.3).
#4 in Best AI Drug Discovery Startups · Lister Score 93.3
Enveda has three drug candidates in human testing, including ENV-294 for eczema..
| Rank | Best AI Drug Discovery Startups | Score |
|---|---|---|
| 1 | Isomorphic Labs | 97.1 |
| 2 | Xaira Therapeutics | 95.8 |
| 3 | Chai Discovery | 94.6 |
| 4 | Enveda | 93.3 |
| 5 | insitro | 92.0 |
| 6 | Formation Bio | 90.7 |
| 7 | Genesis Molecular AI | 89.4 |
| 8 | BigHat Biosciences | 88.1 |
| 9 | Terray Therapeutics | 86.7 |
| 10 | Cradle | 85.3 |
Frequently asked questions
How does Enveda rank on Lister?
Enveda is ranked 4th of 10 in Best AI Drug Discovery Startups (Lister Score 93.3).
Appears in
Add this badge to your site
If you work at Enveda, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.